

NCT02630628 Raw comparison:

Summary:
CHIA has 17 criteria while your personal folder has 18 criteria
Total found criteria: 17/17
Total not Found: 0/17
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Biopsy-proven LN Class III/IV±V (ISN/RPS 2003)     │ Biopsy-proven LN Class III/IV±V (ISN/RPS 2003)     │
│ with biopsy performed within 12 weeks of           │ with biopsy performed within 12 weeks of           │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive anti-dsDNA                                │ Positive anti-dsDNA                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active LN with proteinuria (urine                  │ Active LN with proteinuria (urine                  │
│ protein/creatinine ratio >1 0 or 24-hr urine       │ protein/creatinine ratio \>1 0 or 24-hr urine      │
│ protein >1 0 g at baseline) with or without        │ protein \>1 0 g at baseline) with or without       │
│ hematuria                                          │ hematuria                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Both 'incident' (i e new) patients and 'flare'     │ Both 'incident' (i e new) patients and 'flare'     │
│ patients can be included                           │ patients can be included                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal disease unrelated to SLE (e g diabetes       │ Renal disease unrelated to SLE (e g diabetes       │
│ mellitus other glomerular or tubulointerstitial    │ mellitus other glomerular or tubulointerstitial    │
│ disease renovascular disease) or transplanted      │ disease renovascular disease) or transplanted      │
│ kidney                                             │ kidney                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Estimated glomerular filtration rate (eGFR by      │ Estimated glomerular filtration rate (eGFR by      │
│ MDRD) =20 mL/min per 1 73 m2 or serum creatinine   │ MDRD) ≤20 mL/min per 1 73 m2 or serum creatinine   │
│ >300 micromol/L (3 39 mg/dL) at screening          │ \>300 micromol/L (3 39 mg/dL) at screening         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal biopsy showing cellular or fibrocellular     │ Renal biopsy showing cellular or fibrocellular     │
│ crescent in more than 25% of glomeruli             │ crescent in more than 25% of glomeruli             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ CNS or other severe organ manifestation of lupus   │ CNS or other severe organ manifestation of lupus   │
│ that necessitate aggressive immunosuppressive      │ that necessitate aggressive immunosuppressive      │
│ therapy on its own                                 │ therapy on its own                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Co-morbidities that require corticosteroid therapy │ Co-morbidities that require corticosteroid therapy │
│ (e g asthma inflammatory bowel disease)            │ (e g asthma inflammatory bowel disease)            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with prednisolone (or prednisone or      │ Treatment with prednisolone (or prednisone or      │
│ equivalent) at >20 mg/D for over 4 weeks within    │ equivalent) at \>20 mg/D for over 4 weeks within   │
│ the past 3 months                                  │ the past 3 months                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with MMF at >1 5 g/D for over 4 weeks    │ Treatment with MMF at \>1 5 g/D for over 4 weeks   │
│ within the past 3 months                           │ within the past 3 months                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity or intolerability to        │ Known hypersensitivity or intolerability to        │
│ prednisolone (or prednisone or equivalent) TAC or  │ prednisolone (or prednisone or equivalent) TAC or  │
│ MMF at a dose of 1 25 g or below per day           │ MMF at a dose of 1 25 g or below per day           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who are already on treatment with TAC     │ Subjects who are already on treatment with TAC     │
│ cyclosporine or any other calcineurin inhibitor    │ cyclosporine or any other calcineurin inhibitor    │
│ for over 4 weeks within the past 12 months         │ for over 4 weeks within the past 12 months         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with cyclophosphamide leflunomide or     │ Treatment with cyclophosphamide leflunomide or     │
│ methotrexate for over 2 weeks or use of biological │ methotrexate for over 2 weeks or use of biological │
│ agent(s) regardless of duration within the past 6  │ agent(s) regardless of duration within the past 6  │
│ months (Note prior use of azathioprine mizoribine  │ months (Note prior use of azathioprine mizoribine  │
│ intravenous immunoglobulins and anti-malarials is  │ intravenous immunoglobulins and anti-malarials is  │
│ allowed)                                           │ allowed)                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled hypertension with systolic BP >160    │ Uncontrolled hypertension with systolic BP \>160   │
│ mmHg or diastolic BP >95 mmHg                      │ mmHg or diastolic BP \>95 mmHg                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant or breastfeeding            │ Women who are pregnant or breastfeeding            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women with childbearing potential or their male    │ Women with childbearing potential or their male    │
│ partners who refuse to use an effective birth      │ partners who refuse to use an effective birth      │
│ control method                                     │ control method                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛